570 related articles for article (PubMed ID: 19916299)
1. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
Feldman SR; Koo JY; Johnson LA; Preston NJ
Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
[TBL] [Abstract][Full Text] [Related]
2. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis.
Lebwohl M; Colón LE
Cutis; 2007 Nov; 80(5 Suppl):29-40. PubMed ID: 18154221
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis.
Jarratt MT; Clark SD; Savin RC; Swinyer LJ; Safley CF; Brodell RT; Yu K
Cutis; 2006 Nov; 78(5):348-54. PubMed ID: 17186795
[TBL] [Abstract][Full Text] [Related]
4. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial.
Menter A
Cutis; 2007 Nov; 80(5 Suppl):12-9. PubMed ID: 18154219
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial.
Feldman SR
Cutis; 2007 Nov; 80(5 Suppl):20-8. PubMed ID: 18154220
[TBL] [Abstract][Full Text] [Related]
6. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.
Sofen H; Hudson CP; Cook-Bolden FE; Preston N; Colón LE; Colón LE; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2011 Aug; 10(8):885-92. PubMed ID: 21818510
[TBL] [Abstract][Full Text] [Related]
7. Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis.
Menter A
Cutis; 2012 Feb; 89(2):89-94. PubMed ID: 22474733
[TBL] [Abstract][Full Text] [Related]
8. Relevance of the COBRA trial in current psoriasis practice.
Koo JY
Cutis; 2007 Nov; 80(5 Suppl):4-11. PubMed ID: 18154218
[TBL] [Abstract][Full Text] [Related]
9. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis.
Hudson CP; Kempers S; Menter A; Papp K; Smith S; Sofen H; Colón LE; Johnson LA; Gottschalk R
Cutis; 2011 Oct; 88(4):201-7. PubMed ID: 22106730
[TBL] [Abstract][Full Text] [Related]
10. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
Beutner K; Chakrabarty A; Lemke S; Yu K
J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
[TBL] [Abstract][Full Text] [Related]
11. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
12. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
13. A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg/g ointment in the management of plaque psoriasis.
Brodell RT; Bruce S; Hudson CP; Weiss JS; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2011 Feb; 10(2):158-64. PubMed ID: 21283920
[TBL] [Abstract][Full Text] [Related]
14. Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
Menter MA; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2012 Nov; 11(11):1348-54. PubMed ID: 23135087
[TBL] [Abstract][Full Text] [Related]
15. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
[TBL] [Abstract][Full Text] [Related]
16. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
Kimball AB; Gold MH; Zib B; Davis MW;
J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
[TBL] [Abstract][Full Text] [Related]
17. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
Decroix J; Pres H; Tsankov N; Poncet M; Arsonnaud S
Cutis; 2004 Sep; 74(3):201-6. PubMed ID: 15499763
[TBL] [Abstract][Full Text] [Related]
18. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
19. Improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray.
Brodell R; Preston N
J Drugs Dermatol; 2012 Dec; 11(12):1455-9. PubMed ID: 23377516
[TBL] [Abstract][Full Text] [Related]
20. An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis.
Menter A; Sofen H; Smith S; Papp K; Kempers S; Hudson CP; Colón LE; Johnson LA; Gottschalk R
Cutis; 2011 Jul; 88(1):46-51. PubMed ID: 21877508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
